Digital Therapeutics

Companies will utilize collaboration to develop prescription digital therapeutics for schizophrenia.

ResearchAndMarkets.com releases "Digital Therapeutics: A New Age Medicine"

Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Success in developing patient monitoring and management for melanoma sets stage for expanded partnership.

More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.

As support increases, adoption by Medicare and Medicaid would provide even greater access for patients.

With more promising products emerging, investment risks remain.